Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference for Subcutaneous vs Intravenous Nivolumab and Nivolumab/Relatlimab in Melanoma
NCT06101134Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Primary completion
- Apr 2025
- Countries
- 5
01
Overview
A Phase 2 trial of nivolumab, relatlimab in melanoma, sponsored by Bristol Myers Squibb. Started Nov 2023; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06101134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101134.